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Abstract
Background: Many pharmaceutical drugs are known to be ineffective or have negative side effects in a substantial
proportion of patients. Genomic advances are revealing that some non-synonymous single nucleotide variants
(nsSNVs) may cause differences in drug efficacy and side effects. Therefore, it is desirable to evaluate nsSNVs of
interest in their ability to modulate the drug response.
Results: We found that the available data on the link between drug response and nsSNV is rather modest. There
were only 31 distinct drug response-altering (DR-altering) and 43 distinct drug response-neutral (DR-neutral)
nsSNVs in the whole Pharmacogenomics Knowledge Base (PharmGKB). However, even with this modest dataset, it
was clear that existing bioinformatics tools have difficulties in correctly predicting the known DR-altering and DR-
neutral nsSNVs. They exhibited an overall accuracy of less than 50%, which was not better than random diagnosis.
We found that the underlying problem is the markedly different evolutionary properties between positions
harboring nsSNVs linked to drug responses and those observed for inherited diseases. To solve this problem, we
developed a new diagnosis method, Drug-EvoD, which was trained on the evolutionary properties of nsSNVs
associated with drug responses in a sparse learning framework. Drug-EvoD achieves a TPR of 84% and a TNR of
53%, with a balanced accuracy of 69%, which improves upon other methods significantly.
Conclusions: The new tool will enable researchers to computationally identify nsSNVs that may affect drug responses.
However, much larger training and testing datasets are needed to develop more reliable and accurate tools.
Background
Pharmaceutical drugs have been critical to maintaining
global health in the 21st century [1,2]. While they are fre-
quently prescribed for patients worldwide, it is now clear
that most of them are effective in only a modest fraction
of the patients [3,4]. Furthermore, they may even cause
adverse reactions in many people, leading to 100,000
deaths per year [5-7]. Differences in individual drug
responses are due to many factors, including environment,
dosage, physiological traits, and genetics [8]. Of these, the
focus on genetic variants underlying differential drug
response and toxicities is growing [9-11]. It is thought that
a patient genetics-centric prescription may be useful to
avoid ineffective treatments and side effects [12], especially
because advances in DNA sequencing technology now
allow for high throughput analysis of personal genomes
[13-15]. In particular, exome sequencing has now become
affordable and it will be useful as a first step in identifying
any personal amino acid altering variants in proteins-of-
interest that may influence drug response [12]. However,
personal exomes are full of novel, rare variants [16], which
necessitate an initial computational screening to identify
candidate nsSNVs.
Computational prediction of the functional impact of
nsSNVs has been routinely used in discovering variants
associated with Mendelian diseases and complex dis-
eases [17-21]. Several bioinformatic tools reported pre-
diction accuracy as high as 89% [22-24]. Although it is
intuitive to directly borrow these methods for the
purpose of screening nsSNVs on their drug-response
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phenotypes, the performance of these tools in this speci-
fic domain is never evaluated. In fact, because these
bioinformatic methods heavily rely on the evolutionary
properties of nsSNVs, they will perform well only if dis-
ease-associated variants and drug-response-associated
variants share similar evolutionary patterns.
Therefore, the initial focus of this study was to evaluate
existing bioinformatics tools in the realm of differential
drug responses. Our results indicated that there is a need
for developing a new prediction model to improve the
accuracy of diagnosis. We then examined the evolution-
ary properties (e.g., conservation profiles and the nature
of mutational changes) that distinguish drug-response
altering (DR-altering) from drug-response neutral (DR-
neutral) nsSNVs. Based on these findings, we present our
new statistical model, called Drug-Evolutionary Diagnosis
(Drug-EvoD), for testing nsSNVs on their effect on drug
responses. However, at the end, we pointed out that
much larger training and testing datasets are needed to
develop more reliable and accurate tools.
Results and discussion
Known drug-related nsSNVs
Pharmacogenomics Knowledge Base (PharmGKB, [2,15])
is a publicly available database dedicated to understand-
ing how genetic variations in the human genome lead to
variations in clinical responses to various drugs. It also
provides integrated knowledge on relationships among
genes, drugs, and diseases from clinical trials, case stu-
dies, genome-wide association studies, and functional in
vivo and in vitro studies. Although over a thousand of
entries are recorded in PharmGKB, most of them corre-
spond to multiple observations involving the same
nsSNVs and the same drug. Ultimately, only 263 unique
nsSNVs in 178 proteins were found (see Figure S1 in
Additional File 1 and Additional File 2 for the distribu-
tion of the nsSNVs across different family of proteins
and corresponding data). After careful curations (see
Methods), we identified a total of 74 nsSNVs in 59 pro-
teins (Figure 1), for which multiple evidences supported
their unambiguous effect on drug responses. This data-
set (DrugVar) consists of 31 DR-affecting nsSNVs (true
positives, see Table S1 in Additional File 3) and 43 DR-
neutral nsSNVs (true negatives, see Table S2 in Addi-
tional File 4). It was used as the control data to test the
performance of various computational tools, and served
as the training data to build new statistical models. To
our best knowledge, DrugVar is the first well-curated
dataset depicting the genotype-phenotype relationship
for drug responses.
Effectiveness of existing methods
We chose to test the performance of two widely used
methods, SIFT [24] and PolyPhen-2 [22], and a new tool
that improves upon their accuracy in some cases (EvoD
[23]). These prediction tools were originally designed to
forecast the functional impact of an nsSNV in disease
domains. However, when applied to the drug-response
domain using DrugVar dataset, all three methods showed
rather low overall accuracies (Table 1). Only 39% - 53%
DR-affecting nsSNVs and 46% - 60% DR-neutral nsSNVs
were correctly diagnosed. Their average accuracies are in
the range of 44% and 52%, which is not much different
from random diagnosis. This raised the doubt on the use-
fulness of existing tools for diagnosing nsSNVs with dif-
ferential drug responses.
One reason for this ineffectiveness may be that the
statistical models for all these tools are trained using
Mendelian disease-associated nsSNVs [25,26], which
may not be similar to nsSNVs associated with drug
responses. This was indeed the case. While Mendelian
disease mutations are highly overabundant at evolutio-
narily conserved sites as compared to common popula-
tion polymorphisms [23], DR-affecting nsSNVs do not
show such strong tendencies (Figure 2a). The average
evolutionary rate for positions harboring DR-altering
nsSNVs (1.33/site/byr) is not significantly different from
that of positions harboring DR-neutral nsSNVs (1.49/
site/byr; P < 0.6). In addition, the average biochemical
severity of nsSNVs implicated in DR-affecting nsSNVs is
not significantly different from that for DR-neutral
Figure 1 Frequency distributions of DrugVar nsSNVs in
proteins. Majority of the proteins contain only one nsSNV that is
associated with drug responses.
Table 1 Performance of EvoD, PolyPhen-2 and SIFT when
analyzing PharmGKB variants.
Diagnosis Rate
Method TNR FPR FNR TPR Balanced Accuracy
EvoD 49% 51% 61% 39% 44%
PolyPhen-2 60% 40% 55% 45% 52%
SIFT 46% 54% 47% 53% 50%
Note – TPR: True Positive Rate (sensitivity), FPR: False Positive Rate, TNR: True
Negative Rate (Specificity), FNR: False Negative Rate
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nsSNVs (67 vs. 76; P < 0.4, Figure 2b). This is in stark
contrast to the pattern observed for Mendelian disease
associated variants that show a 50% higher biochemical
severity for Mendelian nsSNVs as compared to common
population polymorphisms [27]. These observations
indicated that the statistical models trained using disease
nsSNVs (e.g., EvoD, PolyPhen-2, and SIFT) are not sui-
table for diagnosing DR-affecting nsSNVs.
An evolutionary diagnosis model specific to drug-
responses
This prompted us to develop a prediction model specifi-
cally trained on nsSNVs associated with drug responses
(Drug-Evolutionary Diagnosis, Drug-EvoD). We began
with 12 evolutionary and biochemical features (see Meth-
ods), which were also tested in the original EvoD model
[23] that is built for diagnosing disease variants. A feature
selection step was applied to identify features that showed
a significant power to discriminate between DR-altering
and DR-neutral nsSNVs. These features were then used to
construct a linear regression model for predictive pur-
poses. This new model (Drug-EvoD) achieved a balanced
accuracy of 69%, which is significantly higher than other
methods. Such improvement is most likely resulted from
an increased true positive rate, which are 84% in Drug-
EvoD and 39%-53% in other methods (Table 1, Figure 3).
The true negative rate, however, is similar between Drug-
EvoD (53%) and other methods (49%-60%).
We then examined the Drug-EvoD model (Table 2) and
compared it to the EvoD model [23]. We found that these
two models share some fundamental similarities as the
coefficients of features are almost always in the same
direction. However, significant differences exit. Some
EvoD features, such as indel-based entropy, turned out to
be not informative in Drug-EvoD. Conversely, some fea-
tures not in the EvoD model play important roles in Drug-
EvoD, such as evolutionary rate estimated among primates
and mammals. Even for those features that are shared
between these two models, their coefficients are very dif-
ferent. For example, the coefficient of evolutionary rate
among vertebrates in Drug-EvoD (-29.5) is only half of
that in EvoD at less-conserved sites (-55.2). In summary,
we found that the Drug-EvoD model is specifically adapted
to differential drug responses and thus achieves better per-
formance than other disease-centered predictive models.
Conclusions
In this study, we tested the possibility of repurposing
computational methods of diagnosing disease variants to
predict nsSNVs associated with drug-responses. We
found that these tools have rather low accuracies in this
domain. This is not surprising because these predictive
methods heavily rely on the evolutionary patterns of var-
iants associated with Mendelian diseases, which are
under strong purifying selections across species [28,29].
However, we do not expect variants associated with
drug responses to share this pattern, as it is unlikely
Figure 2 Comparison between DR-neutral and DR-affecting nsSNVs on evolutionary conservation and biochemical severity. Cumulative
frequency distributions were plotted on evolutionary rate (A) and the Grantham distance (B) for DR-neutral (solid line) and DR-affecting (broken
line) variants in DrugVar. Evolutionary rate was estimated using Kumar et al. [27] method applied to the multiple alignments of 46 species
obtained from the UCSC Genome Browser [31].
Figure 3 Performance of Drug-EvoD, EvoD, PolyPhen-2 and
SIFT methods tested on the DrugVar dataset. True positive rate
(TPR, solid bars), true negative rate (TNR, open bars), and balanced
accuracy (hatched bars) were plotted.
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that differential drug responses will lead to significant
fitness shift in the long-term evolutionary history of
humans. This is supported by our observations that DR-
affecting nsSNVs and DR-neutral nsSNVs have similar
evolutionary rate and biochemical severity (Figure 2).
On the other hand, DR-affecting nsSNVs clearly cause
functional changes of proteins, which can be detected
using evolutionary data, although it may not show pat-
terns of strong purifying selection.
We then presented a predictive model (Drug-EvoD) spe-
cifically trained on nsSNVs with differential drug
responses. It was based on a number of features, including
long-term evolutionary history of protein positions and
alleles, and biochemical severity of variants. Drug-EvoD
was the first attempt on exploring ways to identify drug-
associated variants with available data. It significantly
improves the prediction accuracy upon other models that
were developed for identify disease-associated variants. As
genetic variants have been found to have a major func-
tional impact on drug response, this kind of computational
tools have the potential to give physicians in clinical set-
tings primary information on whether a patient will be sub-
jected to adverse drug response or lack of efficacy, and will
help them to prescribe more effective drugs with minimum
adverse side effects based on human gene variations.
However, Drug-EvoD was trained on a rather small set
of nsSNVs in DrugVar. Although it shows superior per-
formance than existing methods, we believe that such
tools will be more reliable with the increase of well-
annotated variants and drug response associations. In
the future, the accuracy of Drug-EvoD can be further
improved with additional features, including 3-D struc-
tural models of proteins and drug compounds, which
will enable us to predict drug efficiency using molecular
docking techniques.
In conclusion, Drug-EvoD represents an initial effort
toward computationally modeling the genotype-phenotype
relationship on drug responses to make predictions. It
demonstrated the feasibility of this new approach. Subse-
quent methods to improve the size of the control datasets
and to construct models with advanced molecular docking
algorithms will become invaluable to the research and
clinical communities.
Methods
Data collection
We used the latest version of PharmGKB [2,15] (accessed
on 05/02/2013) to retrieve all available data (filename:
var_pheno_ann.tsv) about associations between nsSNVs
and their drug response phenotypes, along with informa-
tion on the drug involved. A total of 1,152 entries were
obtained. Redundant entries that corresponded to multi-
ple observations involving the same nsSNVs and the
same drug were consolidated into 263 unique nsSNVs in
178 proteins. For each of these nsSNVs, we extracted the
type of change and their associated drug efficacy (the
ability of a drug to produce a desired effect) and toxicity
(abnormal buildup of prescription medication in the
bloodstream).
The PharmGKB database presents specific “Strength of
Evidence” levels for variant annotations based on clinical
results [30]. In the current study, we focused only on var-
iants that have significant clinical annotation level of evi-
dences (Level1A, Level1B and Level2A). That is, variants
that were based on a single case report, a study with non-
significant results, and studies lacking clear evidence of
associations were regarded as having low evidence strength
and were not considered. Only variants with high evidence
strength in the expert annotations were retained. With this
stringent curation and filtering, we obtained 31 distinct
nsSNVs in 27 proteins that could be unambiguously used
as DR-affecting (true positives, see Table S1 in Additional
File 3) and 43 distinct nsSNVs in 36 proteins that could be
unambiguously used as DR-neutral (true negatives, see
Table S2 in Additional File 4). This composed of the Drug-
Var dataset. These nsSNVs were cross-referenced on NCBI
dbSNP identifers (rsIDs) to retrieve their chromosomal
locations in the hg19 human genome build.
Evolutionary features
For each nsSNV in the DrugVar dataset, multiple species
alignments were obtained from the UCSC Genome Brow-
ser [31] based on its chromosomal location. Using these
alignments, we obtained twelve features for each nsSNV.
The first set was the absolute evolutionary rate (r) of
amino acid change of the position where the nsSNV was
found. It quantifies the degree of long-term natural selec-
tion against amino acid change and is a measure of the
functional importance of the position [27,32-34]. The
Table 2 Coefficients of the 12 features in the Drug-EvoD
model.
Parameter Species Coefficient
Primates-only 12.2
Evolutionary Rate Mammals-only 22.3
All-species -29.5
Primates-only ns
Evolutionary Timespan (Position) Mammals-only ns
All-species 12.1
Primates-only ns
Evolutionary Timespan (Variant) Mammals-only 21.8
All-species -19.9
Grantham Value -9.8
Others Blosum62 -11.6
Entropy2 ns
Note –Features that were removed in the feature selection step are
indicated by ns.
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second set was positional evolutionary timespan (pETS)
for each position, which measures the retention of a posi-
tion over evolutionary time [32-34]. The third set was
mutational evolutionary timespan (mETS), which mea-
sures the prevalence of an nsSNV at the affected position
across multiple species, effectively highlighting the degree
of evolutionary neutrality of the mutant. These evolution-
ary parameters were estimated using 46 diverse species
(vertebrates and lamprey), only mammal (36 species), and
only primates (10 species) following Kumar et al. [27]. The
fourth set consists of biochemical severity of the variant,
which was measured using Grantham index [35], and a
simple estimate of the amino acid substitution probability
as captured in the BLOSUM62 matrix [36]. It also con-
tains indel-based entropy that is the frequency of indels/
deletions. Normalization was applied to each feature such
that it had a mean value of 0 and standard deviation of 1.
Drug-EvoD modeling
The statistical model to predict differential drug response
for an nsSNV was derived by following the EvoD frame-
work [23]. We used the DrugVar dataset as the training
and testing data. The drug responses were regarded as the
response variable (D, 100 for positive controls, 0 for nega-
tive controls). The 12 features of nsSNVs composed of a
feature matrix (F). Within a sparse-learning framework
[37-40], we first performed a feature selection step to iden-
tify features with significant power to discriminate between
DR-affecting (positive controls) and DR-neutral (negative
controls) nsSNVs. This step involved minimization of the
l1-norm regularized least square loss using a stability selec-
tion procedure that tested a series of regularization para-
meters [41]. Features that were assigned with non-zero
coefficient values in more than 95% of subsamples were
retained. For each regularization parameter, we also
obtained the weights of corresponding features that best
explain the phenotype. If the weight of a feature accounted
for less than 5% of the total weight of all features, it was
removed due to small effect size. This procedure allowed
us to select features that have the most discriminative
power between DR-affecting nsSNVs and DR-neutral
nsSNVS. In the final model, the weights of selected features
were determined that yielded the highest classification
accuracy in a balanced subsampling procedure with stan-
dard 10-fold cross-validations. This model produced an
impact score for each nsSNV. If the impact score is greater
than or equal to 50, it was predicted as DR-affecting. If the
impact score is less than 50, it was predicted as DR-neutral.
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